- Home
- RVMD vs ASND Comparison
RVMD vs ASND Comparison
Compare RVMD & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | ASND |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | Denmark |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 14.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RVMD | ASND |
|---|---|---|
| Price | $148.00 | $244.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 16 |
| Target Price | $135.05 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 3.0M | 494.8K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $96.35 |
| Revenue Next Year | $411.49 | $44.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.00 | $151.11 |
| 52 Week High | $155.70 | $250.74 |
Technical Indicators
Market Signals| Indicator | RVMD | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 83.31 | 60.39 |
| Support Level | $93.39 | $190.49 |
| Resistance Level | N/A | $248.60 |
| Average True Range (ATR) | 5.24 | 8.47 |
| MACD | 6.48 | 1.95 |
| Stochastic Oscillator | 90.61 | 83.29 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.